Premium
Management of bleeding in severe factor V deficiency with a factor V inhibitor
Author(s) -
Ardillon L.,
Lefrançois A.,
Graveleau J.,
Fouassier M.,
Ternisien C.,
Sigaud M.,
Fretigny M.,
Archambeaud I.,
Trossaërt M.
Publication year - 2014
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12134
Subject(s) - fresh frozen plasma , recombinant dna , medicine , factor vii , coagulopathy , platelet , immunology , pharmacology , coagulation , chemistry , biochemistry , gene
Factor V ( FV ) inhibitor arises rarely after using fresh frozen plasma ( FFP ) to treat inherited FV deficiency and is often a real therapeutic challenge. Here, we report a patient with a severe FV deficiency who developed such an inhibitor and was then treated with recombinant activated FVII (r FVII a) and platelet concentrates ( PC ). Monitoring was assessed by thrombin generation assay ( TGA ). PC were more effective than r FVII a in treating bleeding, but there was no correlation between the TGA results and clinical efficacy.